Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 19/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.62 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19032310 | 1.00 | MEN1 (0.62) | MEN1KMT2AP2RY12 | |
| SCHEMBL21160537 | 1.00 | MEN1 (0.62) | MEN1KMT2AP2RY12 | |
| SCHEMBL19979068 | 0.96 | MEN1 (0.61) | MEN1KMT2AP2RY12 | |
| SCHEMBL19979056 | 0.96 | MEN1 (0.61) | MEN1KMT2AP2RY12 | |
| SCHEMBL19979058 | 0.96 | MEN1 (0.65) | MEN1KMT2AP2RY12 | |
| SCHEMBL19032305 | 0.96 | MEN1 (0.59) | MEN1KMT2AP2RY12 | |
| SCHEMBL19032271 | 0.95 | MEN1 (0.59) | MEN1KMT2AP2RY12 | |
| SCHEMBL19850562 | 0.93 | MEN1 (0.53) | MEN1KMT2AP2RY12 | |
| SCHEMBL19032298 | 0.90 | MEN1 (0.55) | MEN1KMT2AP2RY12 | |
| SCHEMBL19838148 | 0.90 | MEN1 (0.55) | MEN1KMT2AP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11220517-B2 | Spiro bicyclic inhibitors of menin-MLL interaction | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-11 | — | — | US | disclosed |
| EP-3512857-B1 | SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2021-02-24 | — | — | EP | disclosed |
| US-20190211036-A1 | SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2019-07-11 | — | — | US | disclosed |
| WO-2018050686-A1 | SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11220517-B2 | Spiro bicyclic inhibitors of menin-MLL interaction | BMI1, MLLT1, MEN1 | MEN1 3/4885KMT2A 62/4885P2RY12 3986/4885 |
| US-20190211036-A1 | SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | BMI1, MLLT1, MEN1 | MEN1 3/4885KMT2A 92/4885P2RY12 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.